Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
CodeBreaK 200 Investigators, Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schuler, Hervé Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. SolomonSuresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Björn Stollenwerk, David Waterhouse, Luis Paz-Ares*
Duik in de onderzoeksthema's van 'Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial'. Samen vormen ze een unieke vingerafdruk.